New hope for tough stomach cancers: trial tests Dual-Attack drug combo
NCT ID NCT04982276
Summary
This study is testing a new combination of two immunotherapy drugs, called AK109 and AK104, for people with advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination, given with or without standard chemotherapy, can help control the cancer after the first treatment has stopped working. Researchers will measure how well the tumors shrink, how long the treatment keeps the cancer from growing, and what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact
Conditions
Explore the condition pages connected to this study.